• Klaria posted a Q2 net loss of SEK 12.9 million, narrowing from SEK 20.1 million a year earlier.
• EPS improved to a loss of SEK 0.05; R&D costs fell to SEK 4.4 million.
• Operating cash flow worsened to negative SEK 14.8 million; cash rose to SEK 8.5 million at June 30.
• For Jan-Jun, net sales slid to SEK 0.1 million from SEK 9 million; net loss was SEK 21.5 million.
• Group equity stood at negative SEK 33.6 million, while parent-company equity was SEK 79 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klaria Pharma Holding AB published the original content used to generate this news brief via Cision (Ref. ID: 202608311756BITN____UKPR__SV_20260831-BIT-4522-0) on August 31, 2026, and is solely responsible for the information contained therein.